What is AION Labs

AION Labs is a venture studio focused on creating and growing AI and technology companies for pharmaceutical research and development. It is not a self-service AI application, model API, or software subscription platform.

The studio was formed by pharmaceutical, technology, and investment partners including AstraZeneca, Merck, Pfizer, Teva, AWS, the Israel Biotech Fund, and Amiti Ventures. Its purpose is to connect pharma-defined R&D problems with founders, scientific teams, data, validation opportunities, and early-stage capital.

Core offering

  • Industry-driven problem definition and market validation with pharmaceutical partners.
  • Direct access to pharma R&D experts, champions, data, and real-world validation opportunities.
  • Pre-seed investment and support for creating or seeding AI-first drug-discovery ventures.
  • Company-building support spanning founders and talent, technology, cloud infrastructure, operations, partnerships, and follow-on funding.

Pricing and investment structure

As of August 28, 2026, AION Labs does not publish subscription plans, software licence prices, model rates, or a standard service fee. The official site describes a venture-building and investment model rather than a product-pricing model.

AION Labs says selected startups receive at least US$1 million in pre-seed funding, US$100,000 in AWS cloud credits, free access to its Rehovot facilities, and ongoing mentor support. Investment, equity, and partnership terms are handled directly and depend on the company, technology, participating partners, and development programme; no standard equity percentage is published.

Historical challenge materials sometimes disclose funding packages for a particular founder call. Those figures are programme-specific and are not presented here as a current universal price, investment offer, or entitlement.

Venture-building model

AION Labs works through two broad routes. Venture Creation starts with challenges defined by pharma partners, selects scientific founders, and builds a new company around a validated problem. Venture Seeding works with early-stage companies whose products are still young and where AION Labs and its partners can add industry access, validation, data, investment, and scaling support.

The studio says it has launched nine companies, supported pharmaceutical pilots and collaborations, and helped ventures reach follow-on funding, higher valuations, and strategic transactions. Each resulting company has its own product and commercial model; AION Labs itself should not be evaluated as a catalogue of purchasable AI models.

Why engage AION Labs

AION Labs is relevant to scientific founders and early-stage companies building AI or computational technologies for drug discovery and development. It is also relevant to pharmaceutical partners seeking a structured way to define unmet R&D needs and co-develop new ventures. Organisations looking to buy a ready-made AI tool should instead assess the individual companies created by the studio.

Official sources: AION Labs overview, AION Labs model and partners, Venture Creation and Venture Seeding.